Skip to main content

CERO THERAPEUTICS HOLDINGS, INC.

corporate_fare Company Profile

CERO THERAPEUTICS HOLDINGS, INC.

CEROW·OTC·Life Sciences·CIK 0001870404

CERO THERAPEUTICS HOLDINGS, INC. is an immunotherapy company focused on developing engineered T cell therapeutics for cancer treatment. The company's approach to T cell engineering integrates characteristics of both innate and adaptive immunity into a single therapeutic construct. This platform is designed to redirect patient-derived T cells to eliminate tumors by employing both cytotoxic and phagocytic mechanisms to destroy cancer cells, creating Chimeric Engulfment Receptor T ("CER-T") cells. The company's lead molecule is CER-1236, an autologous T-cell product that targets the TIM-4 ligand tumor antigen. CER-1236 is intended for use in both hematological malignancies and solid tumors. On November 14, 2024, the FDA cleared the Investigational New Drug Application ("IND") for CER-1236 after a brief clinical hold, which was lifted following additional in vitro experiments addressing off-target toxicity. In May 2025, CERO THERAPEUTICS HOLDINGS, INC. initiated a Phase 1 clinical trial to evaluate the safety, potential therapeutic utility, and applicable dose of CER-1236 in patients with acute myeloid leukemia ("AML"). This first-in-human, multi-center, open-label, Phase 1/1b study is designed for patients with relapsed/refractory AML, AML in remission with measurable residual disease, or newly diagnosed patients with TP53 mutated MDS/AML or AML. Additionally, on March 27, 2025, the FDA accepted a second IND application for CER-T cell therapy in non-small cell lung cancer ("NSCLC") and ovarian cancer, with a Phase 1 study anticipated to begin in the first quarter of 2026.

CERO THERAPEUTICS HOLDINGS, INC. (OTC:CEROW) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for CEROW at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-07, rated 9/10. Across its 2 most recent items scored 7 or higher, the top rating is 9/10, with 2 rated 8 or above. Recent SEC coverage for CEROW spans 8-K.

Recent high-impact activity:

  • CERo Therapeutics Sells Operating Subsidiary to SRX Global in Debt-for-Asset Deal
  • CERo Therapeutics Secures $11.7M Senior Secured Financing, Pledges All Subsidiary Assets Including CER-1236 IP

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$19.92M
Op. Cash Flow
-$16.1M
Cash & Equivalents
$1.7M
Debt / Equity
0.00×
Source: 10-K · filed 2026-04-30 · accession 0001213900-26-050302

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 9,375 shares in CEROW as of the October 30, 2026 settlement, unchanged from the prior period — about 1.0 days to cover at its recent average daily volume.

Short interest (bi-monthly positions)9,375 shares as of October 30, 2026
Change vs prior period 0.0%
Days to cover1.00 at avg daily volume of 17,291

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$0.0021
52-week range · as of 2026-10-07 $0.0011 – $0.0623
Market cap
$737.32K
Volume
1K (0.0× avg)
3-mo avg 40K
From SEC filing · 2026-10-07

show_chartPrice Chart

Loading chart...

feed CEROW - Latest Insights

CEROW
Oct 07, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
9
CEROW
Aug 31, 2026, 4:52 PM EDT
Filing Type: 8-K
Importance Score:
8
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets